Epidemiological Evidence of Nosocomial and Zoonotic Transmission of Human T-Cell Leukemia Virus-1 in a Large Survey in a Rural Population of Central Africa.
Cameroon
HTLV-1
central Africa
cross-sectional survey
epidemiology
nosocomial
zoonoses
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 03 2023
28 03 2023
Historique:
received:
04
05
2022
accepted:
21
07
2022
medline:
29
3
2023
pubmed:
23
7
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Central Africa is one of the largest areas of high endemicity for human T-cell leukemia virus-1 (HTLV-1). However, no preventive measures are yet implemented to reduce its transmission, which can be sexual, from mother-to-child, or through contaminated blood products. Rare zoonotic transmissions from nonhuman primates (NHPs) have also been reported in this region. Here we investigated the HTLV-1 prevalence and associated risk factors in a rural population in Cameroon. From 2019 to 2021, we performed a cross-sectional survey in the eastern region of Cameroon. HTLV-1 infection was first screened by ELISA, then tested by western blot and envelope gene targeted polymerase chain reaction. Risk factors associated with HTLV-1 infection were identified by logistic regression in univariable and multivariable analyses. Among 3400 participants, HTLV-1 prevalence was 1.1% (95% confidence interval [CI], .7-1.5). Factors independently associated with HTLV-1 infection were Pygmy ethnicity (adjusted odd ratio [aOR], 2.9; 95% CI, 1.3-6.2), history of surgery (aOR, 6.3; 95% CI, 2.2-17.8), and NHP bite (aOR, 6.6; 95% CI, 2.2-19.8). These results suggest both iatrogenic and zoonotic transmission of HTLV-1 in Cameroon. Further studies are needed to assess the risk of nosocomial transmission of HTLV-1, to guide public health authorities in implementing preventive measures to control HTLV-1 transmission.
Sections du résumé
BACKGROUND
Central Africa is one of the largest areas of high endemicity for human T-cell leukemia virus-1 (HTLV-1). However, no preventive measures are yet implemented to reduce its transmission, which can be sexual, from mother-to-child, or through contaminated blood products. Rare zoonotic transmissions from nonhuman primates (NHPs) have also been reported in this region. Here we investigated the HTLV-1 prevalence and associated risk factors in a rural population in Cameroon.
METHODS
From 2019 to 2021, we performed a cross-sectional survey in the eastern region of Cameroon. HTLV-1 infection was first screened by ELISA, then tested by western blot and envelope gene targeted polymerase chain reaction. Risk factors associated with HTLV-1 infection were identified by logistic regression in univariable and multivariable analyses.
RESULTS
Among 3400 participants, HTLV-1 prevalence was 1.1% (95% confidence interval [CI], .7-1.5). Factors independently associated with HTLV-1 infection were Pygmy ethnicity (adjusted odd ratio [aOR], 2.9; 95% CI, 1.3-6.2), history of surgery (aOR, 6.3; 95% CI, 2.2-17.8), and NHP bite (aOR, 6.6; 95% CI, 2.2-19.8).
CONCLUSIONS
These results suggest both iatrogenic and zoonotic transmission of HTLV-1 in Cameroon. Further studies are needed to assess the risk of nosocomial transmission of HTLV-1, to guide public health authorities in implementing preventive measures to control HTLV-1 transmission.
Identifiants
pubmed: 35867855
pii: 6648723
doi: 10.1093/infdis/jiac312
pmc: PMC10043981
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
752-760Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Virology. 2017 Apr;504:141-151
pubmed: 28193549
PLoS Pathog. 2011 Oct;7(10):e1002306
pubmed: 22046126
Int J Cancer. 1998 May 4;76(3):293-8
pubmed: 9579561
PLoS Negl Trop Dis. 2018 Oct 12;12(10):e0006832
pubmed: 30312301
Am J Trop Med Hyg. 1997 May;56(5):561-5
pubmed: 9180608
J Clin Microbiol. 2012 May;50(5):1663-72
pubmed: 22403426
Lancet Infect Dis. 2020 Jan;20(1):133-143
pubmed: 31648940
J Infect Dis. 2016 Aug 1;214(3):353-60
pubmed: 26768251
Emerg Infect Dis. 2019 Apr;25(4):811-813
pubmed: 30882326
Clin Infect Dis. 2015 Jun 1;60(11):1667-76
pubmed: 25722199
PLoS Negl Trop Dis. 2018 Oct 25;12(10):e0006833
pubmed: 30359373
Vox Sang. 2019 Jul;114(5):451-458
pubmed: 30950074
J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):185-90
pubmed: 11242188
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9
pubmed: 15911757
J Med Virol. 2012 Sep;84(9):1428-36
pubmed: 22825822
J Virol. 1998 Dec;72(12):10316-22
pubmed: 9811783
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
J Gen Virol. 2004 Jan;85(Pt 1):25-29
pubmed: 14718616
J Infect Dis. 1997 Aug;176(2):505-9
pubmed: 9237719
Clin Infect Dis. 2010 Oct 1;51(7):777-84
pubmed: 20735238
Transfus Clin Biol. 2016 Feb;23(1):13-9
pubmed: 26778839
Oncogene. 2005 Sep 5;24(39):6058-68
pubmed: 16155612
J Infect Dis. 2011 May 1;203(9):1316-23
pubmed: 21459818
Arch Virol. 1998;143(5):1029-34
pubmed: 9645208
J Virol. 2017 Apr 28;91(10):
pubmed: 28298599
J Infect Dis. 1999 Dec;180(6):1777-83
pubmed: 10558931
Clin Infect Dis. 2016 Sep 15;63(6):800-803
pubmed: 27325689
PLoS Negl Trop Dis. 2021 Jan 28;15(1):e0008923
pubmed: 33507996
J Infect Dis. 2015 Feb 1;211(3):361-5
pubmed: 25147276